Ország: Szingapúr
Nyelv: angol
Forrás: HSA (Health Sciences Authority)
Disodium clodronate tetrahydrate corresponding to Disodium clodronate
BAYER (SOUTH EAST ASIA) PTE LTD
M05BA02
60.0 mg
INJECTION
INTRAVENOUS
Prescription Only
EVER Pharma Jena GmbH
1990-10-16
Bonefos IV_SG_PI_CCDS 9_28 Nov 2012 1 1. NAME OF THE MEDICINAL PRODUCT Bonefos concentrate for Parenteral infusion 60 mg/ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION IN TERMS OF THE ACTIVE SUBSTANCE(S) 1 ml concentrate for solution for infusion contains 60mg disodium clodronate. One 5 ml ampoule contains 300 mg disodium clodronate. 3. PHARMACEUTICAL FORM Clear and colourless solution. 4. CLINICAL PARTICULARS 4.1 INDICATIONS Treatment of hypercalcemia due to malignancy. Treatment of osteolysis due to malignancy. 4.2 DOSAGE AND METHOD OF ADMINISTRATION Children: Safety and efficacy in pediatric patients have not been established. Elderly: There are no special dosage recommendations for the elderly. Clinical trials have included patients over 65 years and no adverse effects specific to this age group have been reported. Adequate hydration should be ensured, and renal function and serum calcium levels should be monitored before and during treatment. The length of time that a clinically acceptable serum calcium level is maintained after infusion of clodronate varies considerably from patient to patient. The infusion may be repeated if necessary to control the serum calcium level, or alternatively, treatment with oral clodronate may be appropriate. Adult patients with normal renal function: Clodronate is given as an intravenous infusion of 300 mg (one 5 ml ampoule)/ day, diluted into 500 ml of either saline (sodium chloride 9 mg/ml) or 5% glucose (50 mg/ml) solution. The prepared solution is infused over a period of a mi Olvassa el a teljes dokumentumot